stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Return on equity
Beam Therapeutics Inc.'s return on equity over the twelve months to 30 September 2026 was −11.3%, down 3.2 percentage points from fiscal 2025 (−8.11%). Over the past ten years it has ranged from −881.2% (fiscal 2020) to 184.7% (fiscal 2018); the current reading is higher than 67% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −8.11% | 35.83 |
| FY2024 | −43.9% | (28.48) |
| FY2023 | −15.5% | 21.60 |
| FY2022 | −37.1% | 32.07 |
| FY2021 | −69.1% | 812.03 |
| FY2020 | −881.2% | (938.33) |
| FY2019 | 57.2% | (127.53) |
| FY2018 | 184.7% | 169.32 |
| FY2017 | 15.4% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| VRDN Viridian Therapeutics, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| BEAM Beam Therapeutics Inc. | −11.3% |
| XNCR Xencor, Inc. compare | −29.1% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −30.0% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −30.2% |
| MBX MBX Biosciences, Inc. compare | −33.2% |
| IDYA IDEAYA Biosciences, Inc. compare | −38.5% |
| RCUS Arcus Biosciences, Inc. compare | −114.1% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement